Physician profile
Joseph Eichenbaum
NPI 1053301267
$2,223.50
in general payments reported to CMS, 2019-2025
12 companies · $585 in 2025
The $585 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $94.88 · 2021: $228 · 2022: $319 · 2023: $338 · 2024: $511 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $594.47 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $505.69 | 2022-2025 | |
| Amgen INC. | $388.75 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $250.61 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $146.20 | 2020-2024 | Lokelma, Farxiga, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $145.10 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $57.22 | 2019-2024 | |
| Esperion Therapeutics, INC. | $42.93 | 2025 | Nexletol |
| Boston Scientific Corporation | $29.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.14 | 2025 | |
| Novo Nordisk INC | $19.32 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $16.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Eichenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.